Clinical trials: HIV Infection Asymptomatic
HIV Infections
Double-Blind Study of Timunox (Thymopentin) in Asymptomatic HIV-Infected Patients Receiving Either Mono (AZT or ddI) or Combination (AZT / ddI or AZT / ddC) Anti-Retroviral Therapy
To confirm results from a previous study in which the combination of thymopentin plus zidovudine ( AZT ), an antiretroviral agent, slowed disease progression in HIV-infected asymptomatic patients.
- Trial name
- NCT00002109
- Testing
- Thymopentin, Stavudine, Zidovudine
- Where
- 50 sites in United States, Puerto Rico
- Sponsor
- Immunobiology Research Institute
HIV
A Phase 2 Study Of PF-00232798 In HIV Positive Patients
To assess the viral load response, safety, tolerability and pharmacokinetics of multiple oral doses of PF 00232798 in HIV-positive patient volunteers.
- Trial name
- NCT00495677
- Testing
- PF-00232798
- Where
- 2 sites in Germany
- Volunteers
- 43 people
- Sponsor
- Pfizer
HIV Infections
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
To assess the magnitude and duration of the antiviral activity in plasma and the incidence and time to total suppression of detectable HIV RNA in plasma.
- Trial name
- NCT00002176
- Testing
- Hydroxyurea, Nelfinavir mesylate, Stavudine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection
To evaluate the ability of the combination of indinavir, zidovudine, and lamivudine to suppress HIV-1 infection as measured by: (1) the maintenance of HIV-1 serum viral RNA below the limit of detection of the most sensitive…
- Trial name
- NCT00002179
- Testing
- Indinavir sulfate, Lamivudine, Zidovudine
- Where
- 17 sites in United States, Canada
- Volunteers
- 200 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus
To investigate the relationship between the pharmacokinetics and pharmacodynamics of UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).
- Trial name
- NCT00643643
- Testing
- Maraviroc (UK-427,857)
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 41 people
- Sponsor
- ViiV Healthcare
HIV Infections
A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
To conduct a randomized dose-ranging study to evaluate the safety and activity of orally administered low dose interferon alfa-n3 as an immunomodulator in subjects with asymptomatic HIV-1 infection.
- Trial name
- NCT00215852
- Testing
- Alferon LDO
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- AIM ImmunoTech Inc.
HIV Infections
A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell
PRIMARY: To compare the virologic activity (quantitative RNA PCR, quantitative PBMC) of the combination of nevirapine and zidovudine (AZT) versus AZT alone after 3 and 6 months of treatment.
- Trial name
- NCT00002323
- Testing
- Nevirapine, Zidovudine
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
HIV-1
A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061
A phase 2a study to investigate the effects of 7-day monotherapy of UK-453,061 on viral load response in asymptomatic human immunodeficiency virus (HIV) infected subjects, to assess the dose-response relationship, and to assess…
- Trial name
- NCT00348673
- Testing
- UK-453,061
- Where
- 3 sites in Germany
- Volunteers
- 49 people
- Sponsor
- Pfizer
HIV Infection
Antiretroviral Activity and Pharmacokinetics of Deferiprone in Healthy Volunteers and Asymptomatic HIV-infected Subjects
The purpose of this study was to examine the safety, efficacy, and pharmacokinetics of different dosages of deferiprone in subjects with or without HIV infection.
- Trial name
- NCT02191657
- Testing
- Deferiprone
- Where
- South Africa
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- ApoPharma
HIV Infections
Phase II Study of the Safety and Surrogate Marker Efficacy of Butyldeoxynojirimycin (SC-48334) and AZT in Symptomatic HIV-1 Infected Patients With 200 - 500 CD4+ Cells/mm3. (NOTE: Asymptomatic HIV-1 Infected Patients Also Eligible)
To assess the dose-related antiviral effects of SC-48334 and zidovudine (AZT) administered in combination or individually in HIV-1 positive patients with 200 - 500 CD4+ cells/mm3.
- Trial name
- NCT00002079
- Testing
- Butyldeoxynojirimycin, Zidovudine
- Where
- 9 sites in United States
- Sponsor
- G D Searle
HIV Infections
The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms
To obtain preliminary information on the safety, tolerability, and antiretroviral activity of HBY 097 alone or in combination with zidovudine ( AZT ) versus AZT alone. PER 1/19/96 AMENDMENT: AZT monotherapy arm was eliminated.
- Trial name
- NCT00002357
- Testing
- HBY 097, Zidovudine
- Where
- 6 sites in United States
- Volunteers
- 144 people
- Sponsor
- Hoechst Marion Roussel
HIV Infections
Safety and Efficacy of Polyethylene Glycolated IL-2 (PEG IL-2) Plus Zidovudine or Dideoxyinosine in HIV Positive, Asymptomatic and Symptomatic Individuals
To investigate the safety of polyethylene glycolated interleukin-2 (PEG IL-2) given subcutaneously in conjunction with antiviral treatment and to explore the effects of treatment on surrogate markers of efficacy and incidence of…
- Trial name
- NCT00001997
- Testing
- Interleukin-2, Polyethylene Glycolated, Zidovudine, Didanosine
- Where
- United States
- Sponsor
- Chiron Corporation
HIV Infections
Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects (THYMON-11001)
This protocol represents the third in human study of TUTI-16, and is being conducted to gather additional safety and human immunogenicity (anti-HIV-1 Tat titers) data of subcutaneously administered TUTI-16.
- Trial name
- NCT01335191
- Testing
- TUTI-16 (1.0 mg)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Thymon, LLC
Lymphatic Disease, HIV Infections
The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)
To evaluate the safety and tolerance of chronic administration of Retrovir (AZT) in HIV-infected adult patients without clinical manifestations of disease.
- Trial name
- NCT00002048
- Testing
- Zidovudine
- Where
- 22 sites in United States
- Sponsor
- Glaxo Wellcome
HIV Infections
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
PRIMARY: To compare the effect of nevirapine versus placebo alone or in combination with zidovudine (AZT) on CD4 T-cell count and percentage after 3 and 6 months of treatment.
- Trial name
- NCT00002324
- Testing
- Nevirapine, Zidovudine
- Where
- 18 sites in United States
- Volunteers
- 250 people
- Sponsor
- Boehringer Ingelheim
Cytomegalovirus Infections, HIV Infections
The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients
To evaluate the safety and tolerability of multiple escalating doses of 1263W94 administered orally for 28 days in HIV infected patients with asymptomatic CMV shedding.
- Trial name
- NCT00002373
- Testing
- Maribavir
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- Glaxo Wellcome
HIV Infections
An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human Immunodeficiency Virus (HIV)-Infected Subjects
To characterize the pharmacokinetics of orally administered FLT (in a liquid formulation) after single doses in both the fed and fasting states; to assess the effect of food on the oral bioavailability of FLT
- Trial name
- NCT00002260
- Testing
- Alovudine
- Where
- United States
- Sponsor
- Lederle Laboratories
HIV Infections
Phase I Study of Alferon N Injection in Persons With Asymptomatic Human Immunodeficiency Virus (HIV) Infection
To determine the safety and tolerance of subcutaneous injections of natural interferon alpha (IFN) in asymptomatic HIV-positive persons and record its effects on the HIV virus in these individuals.
- Trial name
- NCT00002078
- Testing
- Interferon alfa-n3
- Where
- 2 sites in United States
- Sponsor
- Purdue Frederick
HIV Infections
A Study of Anti-HIV Monoclonal Antibody KD-247
The purpose of this study is to evaluate the safety and tolerability of 3 infusions of KD-247 over 2 weeks in HIV-1 seropositive individuals; to determine the pharmacokinetic parameters of KD-247 when administered as above; and…
- Trial name
- NCT00917813
- Testing
- KD-247, Physiological saline
- Where
- 15 sites in United States
- Volunteers
- 27 people
- Sponsor
- The Chemo-Sero-Therapeutic Research Institute
HIV Infections
A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.
- Trial name
- NCT00002106
- Testing
- Ranitidine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 104 people
- Sponsor
- Glaxo Wellcome